These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 1408760)
1. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates. Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760 [TBL] [Abstract][Full Text] [Related]
2. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Sun LQ; Wang L; Gerlach WL; Symonds G Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Bramlage B; Luzi E; Eckstein F Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100 [TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme. Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281 [TBL] [Abstract][Full Text] [Related]
5. Multitarget ribozyme against the S1 genome segment of reovirus possesses novel cleavage activities and is more efficacious than its constituent mono-ribozymes. Shahi S; Banerjea AC Antiviral Res; 2002 Jul; 55(1):129-40. PubMed ID: 12076757 [TBL] [Abstract][Full Text] [Related]
6. Targeted cleavage of hepatitis E virus 3' end RNA mediated by hammerhead ribozymes inhibits viral RNA replication. Sriram B; Thakral D; Panda SK Virology; 2003 Aug; 312(2):350-8. PubMed ID: 12919740 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952 [TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Ramezani A; Joshi S Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Ojwang JO; Hampel A; Looney DJ; Wong-Staal F; Rappaport J Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10802-6. PubMed ID: 1438280 [TBL] [Abstract][Full Text] [Related]
10. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500 [TBL] [Abstract][Full Text] [Related]
11. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986 [TBL] [Abstract][Full Text] [Related]
13. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid. Ohkawa J; Yuyama N; Taira K Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797 [TBL] [Abstract][Full Text] [Related]
14. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis. Paik SY; Banerjea A; Chen CJ; Ye Z; Harmison GG; Schubert M Hum Gene Ther; 1997 Jun; 8(9):1115-24. PubMed ID: 9189769 [TBL] [Abstract][Full Text] [Related]
15. The effect of structure in a long target RNA on ribozyme cleavage efficiency. Campbell TB; McDonald CK; Hagen M Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806 [TBL] [Abstract][Full Text] [Related]
16. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR. Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Yu M; Poeschla E; Yamada O; Degrandis P; Leavitt MC; Heusch M; Yees JK; Wong-Staal F; Hampel A Virology; 1995 Jan; 206(1):381-6. PubMed ID: 7831794 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication. Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817 [TBL] [Abstract][Full Text] [Related]
19. Transcripts containing a small anti-HIV hammerhead ribozyme that are active in the cell cytoplasm but inactive in vitro as free RNAs. Domi A; Beaud G; Favre A Biochimie; 1996; 78(7):654-62. PubMed ID: 8955908 [TBL] [Abstract][Full Text] [Related]